SCHEMBL19689539

SCHEMBL19689539

CCOC(=O)c1c(C2CC2)cnn1-c1c(Cl)cc(F)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.39
PKM P14618 1/20 0.38
TLR4 O00206 4/20 0.38
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
GABRG2 P18507 2/20 0.37
GABRB3 P28472 2/20 0.37
GABRA5 P31644 2/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
GABRA4 P48169 1/20 0.37
GABRE P78334 1/20 0.37
GABRA6 Q16445 1/20 0.37
GABRG1 Q8N1C3 1/20 0.37
GABRG3 Q99928 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1097050 0.86 PDE4D (0.43) NR1H4KDM4EHSD17B10HTTPOLB
SCHEMBL30035480 0.84 NOD2 (0.41) KDM4EHTTPOLBMEN1ALDH1A1
SCHEMBL24087503 0.84 SMN1; SMN2 (0.45) NR1H4KDM4EHTTPOLBTP53
SCHEMBL2773569 0.82 PDE4D (0.41) NR1H4KDM4EHSD17B10HTTPOLB
SCHEMBL20833878 0.81 HTT (0.40) NR1H4KDM4EHSD17B10HTTPOLB
SCHEMBL2773589 0.79 TP53 (0.40) KDM4EHSD17B10HTTPOLBTP53
SCHEMBL24087507 0.79 TP53 (0.43) PKMKDM4EHTTPOLBTP53
SCHEMBL24087545 0.78 NOD2 (0.38) KDM4EHTTPOLBTP53MEN1
SCHEMBL19698948 0.76 NR1H4 (0.45) NR1H4GABRB3GABRA2GABRB2MAPK1
SCHEMBL19689540 0.72 NR1H4 (0.46) NR1H4GABRB3GABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4534536-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2025-04-09 EP disclosed
CN-117924266-A Compounds that modulate FXR (NR 1H 4) 吉利德科学公司 2024-04-26 CN disclosed
CN-117924267-A Compounds that modulate FXR (NR 1H 4) 吉利德科学公司 2024-04-26 CN disclosed
CN-109476636-B Compounds that modulate FXR (NR 1H 4) 吉利德科学公司 2024-01-09 CN disclosed
US-11739065-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2023-08-29 US disclosed
US-11739065-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2023-08-29 US disclosed
EP-4089072-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2022-11-16 EP disclosed
US-20220204460-A1 FXR (NR1H4) MODULATING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2022-06-30 US disclosed
US-20220204460-A1 FXR (NR1H4) MODULATING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2022-06-30 US disclosed
EP-3587412-B1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2022-05-25 EP disclosed
US-10421730-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2019-09-24 US disclosed
US-10421730-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2019-09-24 US disclosed
EP-3257847-B1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2019-08-21 EP disclosed
EP-3257847-B1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2019-08-21 EP disclosed
WO-2017218330-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2017-12-21 WO disclosed
WO-2017218330-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2017-12-21 WO disclosed
EP-3257847-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2017-12-20 EP disclosed
EP-3257847-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2017-12-20 EP disclosed
US-20170355685-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed
US-20170355685-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11739065-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 NR1H4 1/4885PKM 3202/4885TLR4 378/4885
US-10421730-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 NR1H4 1/4885PKM 3202/4885TLR4 378/4885
US-20170355685-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 NR1H4 1/4885PKM 3202/4885TLR4 378/4885
US-20220204460-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 NR1H4 1/4885PKM 3202/4885TLR4 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.